Abstract:Amyloid- β peptides (Aβ) participate in the development of Alzheimer's disease (AD). AD brains accumulate multiple forms of Aβ peptides, composed of Aβ(1–40/42) with pyroglutamate-Aβ(3–40/42) (pGlu-A β) present as a major portion of Aβ. Several studies estimate that pGlu-A β comprises approximately 50% or more of total A β (Saido et al., 1995; Kuo et al., 1997). The pGlu-Aβ(3–40/42) is hypothesized to facilitate the oligomerization of Aβ(1–40/42) (Schilling et al., 2006) to result in neurotoxicity. The formation of pGlu-Aβ(3–40/42) is produced from the substrate Aβ(3–40/42), which may be generated by a beta-secretase-dependent or -independent mechanism. Cathepsin B has been shown to generate A β(1–40/42) from AD mice expressing APP with the wild-type beta-secretase site (Kindy et al., 2012) expressed in the majority of AD patients. This study, therefore, addresses the role of cathepsin B, possessing wild-type beta-secretase function, in producing pGlu-Aβ(3–40/42). Knockout of the cathepsin B gene was conducted in the APP/Lon mouse model of AD. The APP/Lon mice were also treated with E64d, inhibitor of cathepsin B, by oral administration. Brains were then assessed for levels of pGlu-Aβ(3–40/42) and Aβ(1–40/42), amyloid plaque; animals were evaluated for memory function by the Morris water maze test. Knockout of the cathepsin B gene in the APP/Lon AD mouse model, expressing APP with the wild-type beta-secretase site, was assessed. Knockout of the cathepsin gene resulted in a significant reduction in brain pGlu-Aβ(3–40/42) as well as Aβ(1–40/42). Chemical inhibition of cathepsin B, conducted by oral administration of the E64d inhibitor, in the APP/Lon mice reduced brain pGlu-Aβ(3–40/42) and Aβ(1–40/42). Also, cathepsin B inhibition and gene knockout reduced brain amyloid plaque accumulation and improved memory function in the APP/Lon mice. Cellular studies show that pGlu-Aβ(3–40) is secreted from the regulated secretory pathway of neuronal-like chromaffin cells, and inhibition of cathepsin B (with CA074Me) reduces pGlu-A β(3–40). Results from knockout of the cathepsin B gene in the APP/Lon AD mouse model show that cathepsin B participates in the production of pGlu-Aβ(3–40/42), as well as A β(1–40/42). Cathepsin B inhibitors will likely be effective at reducing neurotoxic pGlu-Aβ(3–40/42), as well as Aβ(1–40/42), for improvement of memory function in AD.

Peptide p3 may play a neuroprotective role in the brain.

A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.

Immunoproteasome Subunit Low Molecular Mass Peptide 2 (LMP2) Deficiency Ameliorates LPS/Aβ1-42-Induced Neuroinflammation

Deficiency of NLRP3 Protects Cerebral Pericytes and Attenuates Alzheimer’s Pathology in Tau-Transgenic Mice

Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity

P2-296: Enhanced Proteolysis of Aβ Peptide Reduces Tau Phosphorylation and Neurofibrillary Tangle Formation in APP/tau Transgenic Mice

A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Aβ42-induced cytotoxicity and increasing microglial phagocytosis.

An 18-mer Peptide Derived from Prosaposin Ameliorates the Effects of Aβ1-42 Neurotoxicity on Hippocampal Neurogenesis and Memory Deficit in Mice.

Conditional Inactivation of Presenilin 1 Prevents Amyloid Accumulation and Temporarily Rescues Contextual and Spatial Working Memory Impairments in Amyloid Precursor Protein Transgenic Mice.

Presenilins Regulate the Cellular Level of the Tumor Suppressor PTEN

Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer’s Disease Model Mice

Reduced SH3RF3 may protect against Alzheimer disease by lowering microglial pro-inflammatory responses via modulation of JNK and NFkB signaling

Hippocampal Proteomic Alteration in Triple Transgenic Mouse Model of Alzheimer's Disease and Implication of PINK 1 Regulation in Donepezil Treatment

ADAM10- and γ-secretase-dependent cleavage of the transmembrane protein PTPRT attenuates neurodegeneration in the mouse model of Alzheimer's disease

Peptidyl-Prolyl Cis/Trans Isomerase Pin1 and Alzheimer’s Disease

Spatiotemporal Activation Of The C/Ebp Beta/Delta-Secretase Axis Regulates The Pathogenesis Of Alzheimer'S Disease

Advances in the β-amyloid precursor protein of Alzheimer's disease

O1–08–02: Cathepsin B Produces Brain Pyro‐glu‐beta‐amyloid in a Transgenic Alzheimer's Disease Mouse Model

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

Pigment Epithelium-Derived Factor Plays a Role in Alzheimer's Disease by Negatively Regulating Aβ42.

Pathological Role of Peptidyl-Prolyl Isomerase Pin1 in the Disruption of Synaptic Plasticity in Alzheimer's Disease.